Asia Pacific Organ Transplant Diagnostics Market 2021-2031

Asia Pacific organ transplant diagnostics market will grow by 10.8% annually with a total addressable market cap of $12,042.8 million over 2022-2031, driven by the growing number of transplantations & prevalence of chronic diseases, the high demand for molecular diagnostic tests, the availability of technologically advanced devices, and the surging investment and expenditure in healthcare and diagnostics. Highlighted with 31 tables and 58 figures, this 123-page report “Asia Pacific Organ Transplant Diagnostics Market 2021-2031 by Offering (Instruments, Test Kits & Consumables, Software & Services), Transplant (Solid Organ, Stem Cell, Soft Tissue), Application (Diagnostics, Translational Research), Technology (Molecular Technologies, Serology, Flow Cytometry, Others), End User (Hospitals and Transplant Centers, Reference Laboratories, Academic and Research Institutions, Others), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific organ transplant diagnostics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2018-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify Asia Pacific organ transplant diagnostics market in every aspect of the classification from perspectives of Offering, Transplant, Application, Technology, End User, and Country. Based on Offering, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Instruments • Test Kits & Consumables o Kits & Assays o Consumables • Software & Services Based on Transplant, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Solid Organ Transplant o Kidney o Liver o Heart o Lung o Pancreas o Kidney-Pancreas o Other Solid Organ Transplants • Stem Cell Transplant • Soft Tissue Transplant By Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Diagnostics o Donor Testing o Recipient Testing • Translational Research By Technology, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Molecular Technologies o PCR o Sequencing o Other Molecular Technologies • Serology • Flow Cytometry • Other Technologies By End User, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Hospitals and Transplant Centers • Reference Laboratories • Academic and Research Institutions • Other End Users Geographically, the following national/local markets are fully investigated: • Japan • China • South Korea • Australia • India • Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines) For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of national markets by Offering, Transplant and Technology over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Selected Key Players: Abbott Laboratories Inc. ARUP Laboratories BAG Health Care GmbH Becton Dickinson and Company bioMérieux S.A. Bio-Rad Laboratories, Inc. CareDx, Inc. Eurofins Scientific F. Hoffmann-La Roche Ltd. Illumina, Inc. Immucor, Inc. Laboratory Corporation of America Holdings Novacyt Group Omixon Ltd. OPKO Health QIAGEN N.V. Quest Diagnostics Incorporated Thermo Fisher Scientific Inc. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)